Reimbursement Scheme Paxneury® (guanfacine)
The health insurer does not fully reimburse Paxneury® 1 mg, 2 mg, 3 mg, 4 mg tablets. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal Contribution to the patient.
Conditions
The TBR is limited to children and adolescents aged 6 to 17 years for whom this medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD), and for whom stimulant medications are not suitable, not well tolerated, or have been shown to be ineffective.
The Personal Contribution for Paxneury® 1 mg, 2 mg, 3 mg, 4 mg that is demonstrably charged to the patient by the health insurer will be fully reimbursed from 1 October 2025 up to a maximum of € 250 per patient per year.
Who can submit a claim
Only patients or their carer can claim the Personal Contribution for Paxneury® 1 mg, 2 mg, 3 mg, 4 mg tabletten online. Pharmacists cannot claim this medicine on behalf of the patient.